http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전자 종이 응용을 위한 비젼 시스템의 심도를 이용한 마이크로입자 카운팅 방법
김승택(Seungtaek Kim),김형태(Hyungtae Kim),이상호(Sangho Lee),김종석(Jongseok Kim),김용권(Yong-Kweon Kim) 대한전기학회 2010 대한전기학회 학술대회 논문집 Vol.2010 No.7
본고는 비젼 시스템에서 피사계 심도(depth of field)를 이용하여 전자 종이 같은 응용분야에 이용되는 마이크로 입자 카운팅 방법에 관한 것이다. 실험에서 평균 직경 10㎛의 마이크로 입자를 두 투명전극 사이에 스페이서(직경:125㎛)로 형성된 공간에 넣어 샘플을 제작하고, 샘플에 전계를 인가하여 입자를 상하판 사이에 위치하도록 하였다. 이 샘플 상단면에서 비젼 시스템을 통해 얻은 원본 이미지를 이미지 히스토그램과 임계치 Thresholding 함수를 이용하여 이진 이미지를 얻었다. National Instrument사 Labwindows CVI와 NI Vision Library를 이용하여 제안된 방법의 프로그램을 제작하고, 눈으로 확인할수 있는 80개의 샘플에 대해서 제작된 프로그램으로 입자 카운팅을 수행하여 카운팅에러를 확인하였다.
Kyung-Ah Kim,Sejoon Lee,Hye Jung Park,Eun Sun Jang,Youn Jae Lee,Sung Bum Cho,Young Suk Kim,In Hee Kim,Byung Seok Lee,Woo Jin Chung,Sang Hoon Ahn,Seungtaek Kim,Sook Hyang Jeong 대한간학회 2023 Clinical and Molecular Hepatology(대한간학회지) Vol.29 No.2
Background/Aims: We used next-generation sequencing (NGS) to analyze resistance-associated substitutions (RASs) and retreatment outcomes in patients with chronic hepatitis C virus (HCV) infection who failed direct-acting antiviral agent (DAA) treatment in South Korea. Methods: Using prospectively collected data from the Korean HCV cohort study, we recruited 36 patients who failed DAA treatment in 10 centers between 2007 and 2020; 29 blood samples were available from 24 patients. RASs were analyzed using NGS. Results: RASs were analyzed for 13 patients with genotype 1b, 10 with genotype 2, and one with genotype 3a. The unsuccessful DAA regimens were daclatasvir+asunaprevir (n=11), sofosbuvir+ribavirin (n=9), ledipasvir/sofosbuvir (n=3), and glecaprevir/pibrentasvir (n=1). In the patients with genotype 1b, NS3, NS5A, and NS5B RASs were detected in eight, seven, and seven of 10 patients at baseline and in four, six, and two of six patients after DAA failure, respectively. Among the 10 patients with genotype 2, the only baseline RAS was NS3 Y56F, which was detected in one patient. NS5A F28C was detected after DAA failure in a patient with genotype 2 infection who was erroneously treated with daclatasvir+asunaprevir. After retreatment, 16 patients had a 100% sustained virological response rate. Conclusions: NS3 and NS5A RASs were commonly present at baseline, and there was an increasing trend of NS5A RASs after failed DAA treatment in genotype 1b. However, RASs were rarely present in patients with genotype 2 who were treated with sofosbuvir+ribavirin. Despite baseline or treatment-emergent RASs, retreatment with pan-genotypic DAA was highly successful in Korea, so we encourage active retreatment after unsuccessful DAA treatment.
( Hye Won Lee ),( Se Rim Oh ),( Dong Yun Kim ),( Yechan Jeong ),( Seungtaek Kim ),( Beom Kyung Kim ),( Seung Up Kim ),( Do Young Kim ),( Sang Hoon Ahn ),( Kwang-hyub Han ),( Jun Yong Park ) 대한간학회 2018 Gut and Liver Vol.12 No.3
Background/Aims: The treatment with daclatasvir plus asu-naprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infec-tion. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients. Methods: In to-tal, 363 patients with chronic hepatitis C were treated with DCV+ASV between August 2015 and January 2017. Finally, we analyzed the data of 270 patients who were monitored for at least 12 weeks after the end of treatment. Results: The mean age was 60.7 years, and females predominated (60.4%). Most patients (64.8%) were treatment-naïve, and 56 patients (20.7%) had cirrhosis. Two hundred fifty-seven (95.2%) and 251 (93.0%) patients achieved end-of-treatment responses and sustained virological responses at 12 weeks posttreatment (SVR12), respectively. The SVR12 rates were higher in patients who were <65 years of age, males, without cirrhosis and had lower HCV RNA levels. All LS values and fibrosis-4 and aspartate aminotransferase-to-platelet ratio in-dex values declined from baseline to the time of assessment of SVR12. Conclusions: The DCV+ASV therapy resulted in a high SVR12 and improved liver fibrosis; the treatment was well tolerated in patients with genotype 1b HCV infections. (Gut Liver 2018;12:324-330)
Awareness of Doctors' Shared Decision-Making in Life-Sustaining Care Decisions
Kim, Dalyong,Lee, Hyun Jung,Yu, Soo-Young,Kwon, Jung Hye,Ahn, Hee Kyung,Kim, Jee Hyun,Seo, Seyoung,Maeng, Chi Hoon,Lim, Seungtaek,Kim, Do Yeun,Shin, Sung Joon Korean Society for Hospice and Palliative Care 2021 한국호스피스.완화의료학회지 Vol.24 No.4
Purpose: At the end of life, communication is a key factor for good care. However, in clinical practice, it is difficult to adequately discuss end-of-life care. In order to understand and analyze how decision-making related to life-sustaining treatment (LST) is performed, the shared decision-making (SDM) behaviors of physicians were investigated. Methods: A questionnaire was designed after reviewing the literature on attitudes toward SDM or decision-making related to LST. A final item was added after consulting experts. The survey was completed by internal medicine residents and hematologists/medical oncologists who treat terminal cancer patients. Results: In total, 202 respondents completed the questionnaire, and 88.6% said that the decision to continue or end LST is usually a result of SDM since they believed that sufficient explanation is provided to patients and caregivers, patients and caregivers make their own decisions according to their values, and there is sufficient time for patients and caregivers to make a decision. Expected satisfaction with the decision-making process was the highest for caregivers (57.4%), followed by physicians (49.5%) and patients (41.1%). In total, 38.1% of respondents said that SDM was adequately practiced when making decisions related to LST. The most common reason for inadequate SDM was time pressure (89.6%). Conclusion: Although most physicians answered that they practiced SDM when making decisions regarding LST, satisfactory SDM is rarely practiced in the clinical field. A model for the proper implementation of SDM is needed, and additional studies must be conducted to develop an SDM model in collaboration with other academic organizations.